• Francesca Sanguedolce, Magda Zanelli, Andrea Palicelli, Alberto Cavazza, Loredana DE Marco, Maurizio Zizzo, Stefano Ascani, Matteo Landriscina, Guido Giordano, Francesco Sollitto, and Domenico Loizzi.
• Unit of Pathology, Riuniti Polyclinic, University of Foggia, Foggia, Italy - francesca.sanguedolce@unifg.it.
• Panminerva Med. 2022 Jun 1; 64 (2): 259-264.

AbstractNeuroendocrine neoplasms (NENs) are a group of disease entities sharing common morphological, ultrastructural and immunophenotypical features, yet with distinct biological behavior and clinical outcome, ranging from benign to frankly malignant. Accordingly, a spectrum of therapeutic options for each single entity is available, including somatostatin analogues (SSA), mTOR-inhibitors, peptide receptor radionuclide therapy (PRRT), non-platinum and platinum chemotherapy. In the last few decades, several attempts have been made to better stratify these lesions refining the pathological classifications, so as to obtain an optimal correspondence between the scientific terminology and, the predictive and prognostic features of each disease subtype, and achieve a global Classification encompassing NENs arising at different anatomical sites. The aim of this review was to analyze, compare and discuss the main features and issues of the latest WHO Classifications of NENs of the lung and the digestive system, in order to point out the strengths and limitations of our current understanding of these complex diseases.

25 keywords...

hide…